WhaleCreep

Casdin Capital, LLC 13F holdings, Q3 2021

Hedge fundSEC filingsCompare with another fundHoldings as of 2021-09-30, filed 2021-11-15

Casdin Capital, LLC disclosed 53 US equity positions worth $4.0bn in its Q3 2021 13F filing. Its largest position is NVTA1EUR at 8.7% of the reported book, followed by BLFS and EXK. Versus Q2 2021 it opened 7 new positions, added to 9, reduced 5 and exited 8.

$4.0bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
53
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
8.7%
Largest position
The largest single position as a share of the reported equity book.
52.7%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
26
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2021: 7 new, 9 added, 5 reduced, 8 exited

50 of 53
NVTA1EUR INVITAE CORP–8.7%$347m12.20m0.0%held
BLFS BIOLIFE SOLUTIONS INCHealthcare8.0%$320m7.57m+1.7%added
EXK EXACT SCIENCES CORPBasic Materials5.6%$225m2.36m0.0%held
PACB PACIFIC BIOSCIENCES CALIF INHealthcare5.1%$204m7.99m+60%added
FATE FATE THERAPEUTICS INCHealthcare5.0%$202m3.40m0.0%held
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare4.7%$189m1.00m0.0%held
MXCT MAXCYTE INCHealthcare4.3%$171m13.97m–new
2655787D BLUEPRINT MEDICINES CORP–4.0%$159m1.55m0.0%held
SLGCUSD SOMALOGIC INC–3.8%$154m12.39m–new
VERVE THERAPEUTICS INC no ticker–3.6%$143m3.04m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare2.9%$116m3.67m+8.7%added
TWST TWIST BIOSCIENCE CORPHealthcare2.7%$107m1.00m0.0%held
SRPT SAREPTA THERAPEUTICS INCHealthcare2.5%$102m1.10m+24%added
CDXS CODEXIS INCHealthcare2.5%$101m4.33m0.0%held
AGIO AGIOS PHARMACEUTICALS INCHealthcare2.5%$99.9m2.17m0.0%held
ABSI ABSCI CORPORATIONHealthcare2.2%$89.8m7.72m–new
DNLI DENALI THERAPEUTICS INCHealthcare2.1%$85.8m1.70m+5.6%added
GINKGO BIOWORKS HOLDINGS INC no ticker–2.1%$83.5m7.20m–new
IPSC CENTURY THERAPEUTICS INCHealthcare2.0%$80.7m3.21m0.0%held
RVMD REVOLUTION MEDICINES INCHealthcare1.9%$77.0m2.80m+21%added
CDNA CAREDX INCHealthcare1.9%$75.6m1.19m0.0%held
TNYA TENAYA THERAPEUTICS INCHealthcare1.8%$74.1m3.59m–new
BEAM BEAM THERAPEUTICS INCHealthcare1.8%$71.2m818,8200.0%held
TNGX TANGO THERAPEUTICS INCHealthcare1.8%$71.0m5.49m–new
DMTKQ DERMTECH INC–1.4%$56.0m1.75m0.0%held
ONC BEIGENE LTDHealthcare1.4%$54.5m150,0000.0%held
ALLO ALLOGENE THERAPEUTICS INCHealthcare1.3%$54.0m2.10m+71%added
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–1.2%$49.0m1.93m+47%added
ADPT ADAPTIVE BIOTECHNOLOGIES CORHealthcare1.2%$48.9m1.44m0.0%held
WGS GENEDX HOLDINGS CORPHealthcare0.9%$38.0m5.00m–new
ALEC ALECTOR INCHealthcare0.9%$37.7m1.65m0.0%held
GBIOGBX GENERATION BIO CO–0.8%$33.2m1.32m−18%reduced
SINGULAR GENOMICS SYSTEMS IN no ticker–0.8%$30.1m2.69m0.0%held
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare0.8%$30.1m1.12m0.0%held
CRSP CRISPR THERAPEUTICS AGHealthcare0.7%$29.8m266,4300.0%held
MAGENTA THERAPEUTICS INC no ticker–0.7%$28.4m3.90m+17%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare0.6%$22.9m1.20m0.0%held
GLUE MONTE ROSA THERAPEUTICS INCHealthcare0.5%$21.4m960,8830.0%held
ZLAB ZAI LAB LTDHealthcare0.5%$20.0m190,0000.0%held
23ANDME HOLDING CO no ticker–0.4%$16.7m1.84m−33%reduced
MASS 908 DEVICES INC–0.3%$13.2m406,5020.0%held
RXRX RECURSION PHARMACEUTICALS INHealthcare0.3%$12.6m548,1560.0%held
ORIC ORIC PHARMACEUTICALS INCHealthcare0.3%$12.6m601,5150.0%held
KRON1USD KRONOS BIO INC–0.3%$12.2m583,4360.0%held
DECIBEL THERAPEUTICS INC no ticker–0.2%$9.0m1.17m−0.1%held
TKNO ALPHA TEKNOVA INC–0.2%$7.5m300,0000.0%held
ORTXUSD ORCHARD THERAPEUTICS PLC–0.1%$5.9m2.58m−20%reduced
SEER SEER INCHealthcare0.1%$5.2m150,0000.0%held
BLIUSD PHENOMEX INC–0.10%$3.9m200,0000.0%held
STOK STOKE THERAPEUTICS INCHealthcare0.08%$3.1m120,0000.0%held

Exited since Q2 2021

8 rows
AMRSEUR AMYRIS INC1.2%$49.1m
CNST CONSTELLATION PHARMCETICLS I1.2%$45.3m
NEO NEOGENOMICS INC0.6%$22.1m
FULC FULCRUM THERAPEUTICS INC0.3%$12.1m
CLOV CLOVER HEALTH INVESTMENTS CO0.2%$9.7m
SGMOQ SANGAMO THERAPEUTICS INC0.2%$6.6m
TURNING POINT THERAPEUTICS I no ticker0.1%$5.9m
ZYUSD ZYMERGEN INC0.03%$1.2m

Sector mix

  • Healthcare65.6%
  • Unclassified28.8%
  • Basic Materials5.6%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters